PBE Invesco Biotechnology & Geno Funds
- 64.598
- -0.416-0.64%
Amgen Unusual Options Activity
Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).And retail traders should know.We noticed this today when the trades showed up on publicly available options h
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
Thursday, the FDA approved Amgen Inc's (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on o
Regeneron Wins Temporary Restraining Order Preventing Eylea Generics
Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Piper Sandl
Reported Earlier, FDA Approves Amgen's IMDELLTRA (Tarlatamab-dlle) The First And Only T-Cell Engager Therapy For The Treatment Of Extensive-Stage Small Cell Lung Cancer
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid TumorIMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Su
Biogen Also Drops Collaboration With Ionis on Angelman Syndrome Candidate
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 48.17% Truist Securities $340 → $340 Maintains Buy 05/03/2024 49.04% HSBC $339 → $342 Maintains
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for amyotrop
Third Point Top Buy and Sells in Q1
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 15 trades.If we con
S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally
The S&P 500, Nasdaq 100 and Dow Jones Industrial Average indices all shattered fresh all-time highs Wednesday, driven by a benign inflation report that boosted risk sentiment among bullish investors.T
Market Whales and Their Recent Bets on GILD Options
Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:GILD) revealed 13 unusual trades.Delving into the details, we foun
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
Eisai Projects Major Growth for Alzheimer's Therapy Leqembi
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. (NYSE:PFE) is a gift.
CNBC Halftime Report Final Trades: Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals, QUALCOMM
CNBC Halftime Report Final Trades: Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals, QUALCOMM
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average annual return of 12.78%. Currently, Regeneron Pharmaceut
Peering Into TG Therapeutics's Recent Short Interest
TG Therapeutics's (NYSE:TGTX) short percent of float has fallen 6.31% since its last report. The company recently reported that it has 35.71 million shares sold short, which is 25.55% of all regular s
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 9.86% on an annualized basis producing an average annual return of 20.63%. Currently, Vertex Pharmaceuticals